catalog number :
MBS9408371
products full name :
SSX Polyclonal Antibody
products short name :
[SSX]
products name syn :
[SSX1; Protein SSX1; Cancer/testis antigen 5.1; CT5.1; Synovial sarcoma, X breakpoint 1; SSX2; SSX2A; SSX2B; Protein SSX2; Cancer/testis antigen 5.2; CT5.2; Synovial sarcoma, X breakpoint 2; Tumor antigen HOM-MEL-40; SSX3; Protein SSX3]
other names :
[protein SSX1; Protein SSX1; protein SSX1; synovial sarcoma, X breakpoint 1; Cancer/testis antigen 5.1; CT5.1; Synovial sarcoma, X breakpoint 1]
products gene name :
[SSX]
other gene names :
[SSX1; SSX1; SSRC; CT5.1; CT5.1]
uniprot entry name :
SSX1_HUMAN
specificity :
SSX Polyclonal Antibody detects endogenous levels of SSX protein.
purity :
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
form :
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
storage stability :
Store at -20 degree C/1 year
tested application :
Western Blot (WB), ELISA (EIA)
app notes :
Western Blot: 1:500 - 1:2000. ELISA: 1:20000. Not yet tested in other applications.
image1 heading :
Western Blot (WB)
other info1 :
Immunogen Type: peptide. Immunogen Description: Synthesized peptide derived from the C-terminal region of human SSX.
other info2 :
Target Name: SSX
products categories :
Total protein Ab
ncbi acc num :
NP_001265620.1
ncbi gb acc num :
NM_001278691.1
ncbi pathways :
Transcriptional Misregulation In Cancer Pathway (523016); Transcriptional Misregulation In Cancer Pathway (522987)
ncbi summary :
The product of this gene belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneous humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. This gene, and also the SSX2 and SSX4 family members, have been involved in t(X;18)(p11.2;q11.2) translocations that are characteristically found in all synovial sarcomas. This translocation results in the fusion of the synovial sarcoma translocation gene on chromosome 18 to one of the SSX genes on chromosome X. The encoded hybrid proteins are likely responsible for transforming activity. Alternative splicing of this gene results in multiple transcript variants. A related pseudogene has been identified on chromosome X. [provided by RefSeq, Jul 2013]
uniprot summary :
SSX1: Could act as a modulator of transcription. A chromosomal aberration involving SSX1 may be a cause of synovial sarcoma. Translocation t(X;18)(p11.2;q11.2). The translocation is specifically found in more than 80% of synovial sarcoma. The fusion products SSXT-SSX1 or SSXT-SSX2 are probably responsible for transforming activity. Heterogeneity in the position of the breakpoint can occur (low frequency). Belongs to the SSX family. Protein type: Oncoprotein; Cancer Testis Antigen (CTA). Chromosomal Location of Human Ortholog: Xp11.23. Cellular Component: nucleus. Molecular Function: nucleic acid binding; transcription corepressor activity. Biological Process: regulation of transcription, DNA-dependent; transcription, DNA-dependent. Disease: Sarcoma, Synovial